[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/yumanity-therapeutics” connections=”true” suffix=””]

Yumanity three integrated platforms are: (1). Several proprietary ultra high-throughput, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; (2). A human neuronal platform, in which neurons produced from the stem cells of patients with disease-causing genetic mutations are used to validate the molecules discovered in yeast; and, (3). A drug-target identification platform that exploits the power of yeast genetics and protein network analyses to elucidate mechanisms of action for pathology correcting molecules as new chemical entities are discovered.